INTERNATIONAL PATENT: NOVARTIS AG FILES APPLICATION FOR "COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS"

GENEVA, May 4 -- NOVARTIS AG (Lichtstrasse 354056 Basel) filed a patent application (PCT/IB2025/060775) for "COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS" on Oct 22, 2025. With publication no. WO/2026/088112, the details related to the patent application was published on Apr 30, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): CHETTY, Jonathan Jaganathan (c/o Novartis Pharmaceuticals Corporation59 Route 10East Hanover, New Jersey 07936), CORTES-CROS, Marta (c/o Novartis Pharma AGLichtstrasse 354056 Basel), FERRETTI, Stephane Raymond Louis (c/o Novartis Pharma...